Investing in North America
Fresenius Kabi remains committed to investing in North American manufacturing and technology to meet growing market demands.
Drug shortages continue to challenge healthcare delivery in Canada and customer needs continue to grow. To help address this, Fresenius Kabi has been investing in state-of-the-art production sites in North America. Our goal is to assure continuous supply of our high quality products, now and in the future.
We are investing heavily in the ongoing expansion of our Grand Island, New York production site and are also investing $250 million in our Melrose Park, Illinois production site. Additionally, Fresenius Kabi’s manufacturing and packaging plant in Wilson, North Carolina is the newest site for our North American network and we intend to make it a global centre for prefilled syringe production.
Our investments are aimed at continuously improving quality and production capacity, including the installation of advanced aseptic filling systems that are state-of-the-art in manufacturing for injectable generic pharmaceuticals. This is all part of our commitment to achieving the highest standards in providing safe, affordable drugs and delivery systems to Canadians across the country.